Success Stories: Pioneering Drug Safety Research Earns EB-2 NIW Approval for Pharmaceutical Sciences Expert

Posted by wegreened on January 30, 2026 in NIW, Pharmaceutical Sciences

Client’s Testimonial:

“Thank you for the time and effort helping me file the case!”

On August 8^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for an ORISE Fellow in the Field of Pharmaceutical Sciences (Approval Notice).

General Field: Pharmaceutical Sciences

Position at the Time of Case Filing: ORISE Fellow

Country of Origin: China

State of Residence at the Time of Filing: Arkansas

Approval Notice Date: August 8^th, 2025

Processing Time: 4 months, 25 days

Case Summary:

We are pleased to share the approval of an EB-2 NIW (National Interest Waiver) petition for a pharmaceutical sciences expert from China, currently serving as an ORISE Fellow. At the time of filing, the client was advancing research on drug-induced liver injury (DILI) with a focus on developing a comprehensive database that integrates findings from animal and in vitro studies, as well as investigating the efficacy of replacing animal testing with in vitro models to predict DILI risks. This work not only promotes animal welfare but also accelerates safer and more cost-effective drug development processes.

Recognized Contributions to the Field:
The client has built a strong research record, authoring six peer-reviewed journal articles, including two as first author, published in leading journals such as Advanced Drug Delivery Reviews, Biomaterials, and Pharmaceutics. These works have garnered 148 citations, demonstrating significant influence among peers, with two articles ranking in the top 1% and top 10% of cited papers in pharmacology and toxicology for their publication years. In addition, the client’s expertise has been recognized through peer review service for respected journals, reinforcing their standing as a trusted evaluator of scientific quality in the field.

Advancing Nationally Significant Research:
The petition highlighted that DILI affects tens of thousands of individuals in the United States annually, posing major public health and drug development challenges. By addressing this issue through cutting-edge methodologies and database creation, the client’s research contributes to safer pharmaceutical products and aligns with U.S. priorities in biotechnology and healthcare innovation. The work also directly supports the national interest by reducing healthcare costs, promoting ethical research practices, and maintaining U.S. competitiveness in biomedical innovation.

NAILG’s Role and Outlook:
NAILG presented a comprehensive petition that successfully demonstrated the client’s qualifications under the Matter of Dhanasar framework, addressing all prongs with strong evidence of merit, national importance, and the client’s ability to advance the proposed endeavor. With this approval, the client is now well-positioned to continue pioneering advancements in DILI research and contribute to the development of safer and more effective pharmaceutical therapies in the United States.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With nearly 64,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Tens of Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to nearly 64,000 in 2025.

Track Record of Success EB-1 and NIW Approvals

(2020.01 - 2024.12)

Category	Approval or Refund^®		Approval or Refiling^TM
Category	Approved Sum	Success Rate	Approved Sum	Success Rate
NIW	28,946	99.52%	3,030	98.31%
EB1A	4,322	91.76%	2,870	88.91%
EB1B	793	98.51%	236	90.77%
Total	34,061	98.44%	6,136	93.39%